



Omonike Arike Olaleye, Ph.D. is an Associate Professor of Pharmacology and Assistant Dean for Student Services in the College of Pharmacy and Health Sciences (COPHS) at Texas Southern University (TSU). She has over 15 years of research experience in drug discovery and development in major pharmaceutical companies (Merck Research Laboratories and Bristol Meyers Squibb) and academia. Her formal training in pharmacology was at the Johns Hopkins University School of Medicine (JHU), Baltimore, Maryland. At JHU, she was awarded prestigious pre-doctoral fellowships from both National Aeronautics Space Administration (NASA) and Merck Research Laboratories. Dr. Olaleye's research efforts have been focused on the discovery and development of new therapeutic agents for treatment of infections caused by: *Mycobacterium tuberculosis*, Human Immunodeficiency Virus (HIV), *Leishmania major*, and *Enterococcus faecalis*. To date, she has discovered and characterized structurally diverse small molecule inhibitors with potent and selective activity against *M. tuberculosis*, *E. faecalis* and *L. major*.

Recently, her work has been on the development of new therapeutic agents for treatment of drug resistant TB and HIV co-infection. TB is the leading cause of death in HIV patients worldwide. The apparent lethal synergy of TB with HIV has made the requirement for the development of new anti-TB and anti-HIV agents more imperative. She has identified and characterized potential drug candidates for chemotherapy of TB and HIV co-infection. Furthermore, she developed a high throughput screening assay to screen for novel inhibitors that have activity against TB and HIV. Dr. Olaleye has received extramural funds such as: NIH/NIAID Center for AIDS Research grant from Baylor-UTHealth, two RCMI-Translational Research Network grants, and Gulf Coast Consortium for Chemical Genomics Welch Foundation. She has established productive collaborations resulting in awarded grants, publications and patents at TSU, Johns Hopkins University and research intensive institutions at the Texas Medical Center (TMC) and outside of the Houston area: The Methodist Hospital Research Institute (Affiliate Member), UT-Health (Adjunct Faculty), University of Texas Medical Branch at Galveston, UT El Paso, University of Houston, Baylor College of Medicine, and University of St. Thomas (Adjunct faculty). She was invited as a discussion leader and Guest Speaker to the TB drug discovery Gordon Research Seminar and Conference in Italy.

Dr. Olaleye is passionate about teaching, training and mentoring students in infectious diseases. Particularly exposing students to many critical steps involved in drug discovery and the importance of multidisciplinary collaborations. She has over 10 years of experience working with promising diverse students who are economically and educationally disadvantaged in the health professions, having mentored over 60 of such students who have progressed successfully in their academics and/or professional career. Presently at TSU, she has

administrative oversight of the Office for Student Services in the College of Pharmacy and Health Sciences serving over 1,300 racially, ethnically and culturally diverse students in six undergraduate and two graduate degree programs. She provides leadership for all COPHS student admissions, orientation, advising, registration, recruitment, retention, and graduation. Recently, her work led to the development of new criteria for the Doctor of Pharmacy admission as well as a novel COPHS Scholar's Academy at TSU for student academic enrichment, mentoring and professional development. The COPHS Scholar's Academy model for mentoring was acknowledged and praised by the evaluation team of Accreditation Council for Pharmacy Education in November 2015.